HIV vaccine acceptability among communities at risk: The impact of vaccine characteristics

Vaccine

Volumn 24, Issue 12, 2006, Pages 2094-2101

  Newman, Peter A ^a   Duan, Naihua ^b   Lee, Sung Jae ^b   Rudy, Ellen T ^c   Seiden, Danielle S ^b   Kakinami, Lisa ^b   Cunningham, William E ^d  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Sexually Transmitted Disease Program   (United States)

^d U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

Author keywords

Conjoint analysis; Consumer preference; HIV vaccines; Latinos; Populations at risk

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ABSENCE OF SIDE EFFECTS; ADULT; ANALYSIS OF VARIANCE; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; EXPERIMENTAL DESIGN; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AIDS VACCINES; COMMUNITY HEALTH SERVICES; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HISPANIC AMERICANS; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; RISK FACTORS; SEXUAL BEHAVIOR;

EID: 32844460492     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.11.013     Document Type: Article

References (52)

1. J. Cohen A setback and an advance on the AIDS vaccine front Science 300 5616 2003 28 29
2. International AIDS Vaccine Initiative (IAVI) Report: ongoing trials of preventative HIV vaccines, updated: August 5, http://www.iavireport.org/ specials/OngoingTrialsofPreventiveHIVVaccines.pdf ; [accessed 24.9.2004].
3. J. Cohen Vaccine results lose significance under scrutiny Science 299 5612 2003 1495
4. Vaxgen announces results of its phase III HIV vaccine trial in Thailand: Vaccine fails to meet endpoints, http://www.vaxgen.com/pressroom/index.html ; [accessed 24.9.2004].
5. D.P. Francis, W.L. Heyward, V. Popovic, P. Orozco-Cronin, K. Orelind, and C. Gee Candidate HIV/AIDS vaccines: lessons learned from the world's first phase III efficacy trials AIDS 17 2 2003 147 156
6. International AIDS Vaccine Initiative (IAVI), http://www.iavi.org/ ; [accessed 24.9.2004].
7. R.D. Klausner, A.S. Fauci, L.N. Corey, G.J. Nabel, H. Gayle, and S. Berkley The need for a global HIV vaccine enterprise Science 300 5628 2003 2036 2039
8. P.B. Gilbert, V.G. DeGruttola, M.G. Hudgens, S.G. Self, S.M. Hammer, and L. Corey What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials J Infect Dis 188 2 2003 179 193
9. J.A. Levy What can be achieved with an HIV vaccine? Lancet 357 9251 2001 223 224
10. R.M. Anderson, and G.P. Garnet Low-efficacy HIV vaccines: potential for community-based intervention programmes Lancet 348 9033 1996 1010 1013
11. D.J. Hu, C.R. Vitek, B. Bartholow, and T.D. Mastro Key issues for a potential human immunodeficiency virus vaccine Clin Infect Dis 36 5 2003 638 644
12. J. Esparza, M.L. Chang, R. Widdus, Y. Madrid, N. Walker, and P.D. Ghys Estimation of "needs" and "probable uptake" for HIV/AIDS preventive vaccines based on possible policies and likely acceptance (a WHO/UNAIDS/IAVI study) Vaccine 21 17-18 2003 2041 2050
13. M.J. Alter, S.C. Hadler, H.S. Margolis, W.J. Alexander, P.Y. Hu, and F.N. Judson The changing epidemiology of hepatitis B in the United States JAMA 263 9 1990 1218 1222
14. Institute of Medicine. Calling the shots: immunization finance policies and practices. National Academy Press, Washington, 2000.
15. M. Schutten, J.B.F. de Wit, and J.E. van Steenbergen Why do gay men want to be vaccinated against hepatitis B? An assessment of psychosocial determinants of vaccination intention Int J STD AIDS 13 2 2002 86 90
16. L.E. Egede, and D. Zheng Racial/ethnic differences in influenza vaccination coverage in high-risk adults Am J Public Health 93 12 2003 2074 2078
17. R.K. Zimmerman, and J.A. Ball Vaccinations in adults: missed opportunities Am Fam Physician 58 4 1998 850 854
18. HIV Vaccines in Canada: Legal and Ethical Issues. A Backgrounder, section 3: vaccine delivery (part 3, 45p.), http://www.aidslaw.ca/Maincontent/issues/ vaccines/backgrounder_part3.pdf ; [accessed 27.9.2005].
19. J.B. de Wit, R. Vet, M. Schutten, and J. van Steenbergen Social-cognitive determinants of vaccination behavior against hepatitis B: an assessment among men who have sex with men Prev Med 40 6 2005 795 802
20. S.D. Rhodes, and K.C. Hergenrather Exploring hepatitis B vaccination acceptance among young men who have sex with men: facilitators and barriers Prev Med 35 2 2002 128 134
21. A. Liau, G.D. Zimet, and J.D. Fortenberry Attitudes about human immunodeficiency virus immunization: the influence of health beliefs and vaccine characteristics Sex Transm Dis 25 2 1998 76 81
22. P.M. Webb, G.D. Zimet, R. Mays, and J.D. Fortenberry HIV immunization: acceptability and anticipated effects on sexual behavior among adolescents J Adolesc Health 2 5 1999 320 322
23. G.D. Zimet, M.J. Blythe, and J.D. Fortenberry Vaccine characteristics and acceptability of HIV immunization among adolescents Int J STD AIDS 11 3 2000 143 149
24. A. Liau, and G.D. Zimet The acceptability of HIV immunization: examining vaccine characteristics as determining factors AIDS Care 13 5 2001 643 650
25. P.A. Newman, N. Duan, E.T. Rudy, K.J. Roberts, and D. Swendeman Posttrial HIV vaccine adoption: concerns, motivators, and intentions among persons at risk for HIV J Acquir Immune Defic Syndr 37 3 2004 1393 1403
26. A.L. Diamant, R.D. Hays, L.S. Morales, W. Ford, D. Calmes, and S. Asch Delays and unmet need for health care among adult primary care patients in a restructured urban public health system Am J Public Health 94 5 2004 783 789
27. M.R. Frankel, M.F. Shapiro, N. Duan, S.C. Morton, S.H. Berry, and J.A. Brown National probability samples in studies of low-prevalence diseases. Part II: designing and implementing the HIV cost and services utilization study sample Health Serv Res 34 5 Part 1 1999 969 992
28. R. Singleton, and B.C. Straits Approaches to Social Research 3rd ed. 1999 Oxford University Press New York
29. NOVA Research Company, http://www.novaresearch.com/ ; [accessed 24.9.2004].
30. P.E. Green, and V. Srinivasan Conjoint analysis in consumer research: issues and outlook J Consumer Res 5 2 1978 103 123
31. P.E. Green, and V. Srinivasan Conjoint analysis in marketing: new developments with implications for research and practice J Marketing 54 4 1990 3 19
32. R.D. Luce, and J.W. Tukey Simultaneous conjoint measurement: a new type of fundamental measurement J Math Psychol 1 1964 1 27
33. J. Hay Conjoint analysis in pharmaceutical research J Managed Care Pharm 8 3 2002 206 208
34. K.A. Phillips, T. Maddala, and F.R. Johnson Measuring preferences for health care interventions using conjoint analysis: an application to HIV testing Health Serv Res 37 6 2002 1681 1705
35. M. Ryan, and S. Farrar Using conjoint analysis to elicit preferences for health care BMJ 320 7248 2000 1530 1533
36. M. Bingham, F.R. Johnson, and D. Miller Modeling choice behavior for new pharmaceutical products Value Health 4 1 2001 1 13
37. R.L. Plackett, and J.P. Burman The design of optimum multifactorial experiments Biometrika 33 1946 305 325
38. M. Ryan, E. McIntosh, and P. Shackley Methodological issues in the application of conjoint analysis in health care Health Econ 7 4 1998 373 378
39. P.A. Newman, N. Duan, E.T. Rudy, and K. Johnston-Roberts HIV risk and prevention in a post-vaccine context Vaccine 22 15-16 2004 1954 1963
40. AIDS Vaccine Advocacy Coalition. Advocacy to accelerate ethical research and global delivery of HIV vaccines, www.avac.org ; [accessed 2.5.2005].
41. D. McCaffrey, N. Duan, and S. Morton Propagation of nonresponse weights for censoring in multi-phase screening in complex sample designs Health Serv Outcomes Res Methodol 1 3-4 2000 213 231
42. The American Association for Public Opinion Research. Standard definitions: final dispositions of case codes and outcome rates for surveys. 3rd ed. Lenexa: AAPOR, 2004, http://www.aapor.org/pdfs/standarddefs2004.pdf ; [accessed on 24.9.2004].
43. S.M. Blower, and A.R. McLean Prophylactic vaccines, risk behavior change, and the probability of eradicating HIV in San Francisco Science 265 5177 1994 1451 1454
44. S.M. Blower, and P. Farmer Predicting the public health impact of antiretrovirals: preventing HIV in developing countries AIDScience 3 11 2003 [accessed on 2.5.2005] http://aidscience.org/Articles/aidscience033.htm
45. R. Johnston AIDSVAX results: an answer, or just more questions? AIDS Patient Care STDs 17 2 2003 47 51
46. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Supplemental Report: AIDS cases by state and metropolitan area of residence, 2000. Atlanta: Centers for Disease Control and prevention, 2002;8(2).
47. D.P. Francis, T. Gregory, M.J. McElrath, R.B. Belshe, G.J. Gorse, and S. Migasena Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3 AIDS Res Hum Retroviruses 14 Suppl. 3 1998 S325 S331
48. D.L. Woodland Jump-starting the immune system: prime-boosting comes of age Trends Immunol 25 2 2004 98 104
49. A.L. Devico, T.R. Fouts, M.T. Shata, R. Kamin-Lewis, G.K. Lewis, and D.M. Hone Development of an oral prime-boost strategy to elicit broadly neutralizing antibodies against HIV-1 Vaccine 20 15 2002 1968 1974
50. P.A. Newman, N. Duan, E.T. Rudy, and P.A. Anton Challenges for HIV vaccine dissemination and clinical trial recruitment: if we build it, will they come? AIDS Patient Care STDs 18 12 2004 691 701
51. E.T. Rudy, P.A. Newman, N. Duan, E.M. Kelly, K.J. Roberts, and D.S. Seiden HIV vaccine acceptability among women at risk: perceived barriers and facilitators to future HIV vaccine uptake AIDS Educ Prev 17 3 2005 253 267
52. S.D. Holmberg The estimated prevalence and incidence of HIV in 96 large US metropolitan areas Am J Public Health 86 5 1996 642 654